NASDAQ: TNYA

Tenaya Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for TNYA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 12:32 UTC.

What Tenaya Therapeutics, Inc. does

Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies and small molecule drugs to treat heart diseases with genetic causes. The company's lead programs are TN-201, a gene therapy for a form of heart disease caused by MYBPC3 gene mutations, and TN-401, a gene therapy for a heart condition caused by PKP2 gene mutations; both are in Phase 1b/2 clinical testing. A third candidate, TN-301, is a small molecule inhibitor being studied for heart failure and other conditions.

Summarized from Tenaya Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for TNYA are available in Oxford Ledge.
Open TNYA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-11

2026-09-11Chief Executive OfficerAward122,000—
2026-09-11Chief Medical OfficerAward49,000—
2026-09-11Chief Executive OfficerStock Option (Right to buy)Award732,500—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

VANGUARD CAPITAL MANAGEMENT LLC7,101,263$5.25M-16.3%
MILLENNIUM MANAGEMENT LLC6,429,648$4.75M+17.8%
CITADEL ADVISORS LLC4,566,774$3.38M+8.7%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-06-29Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-02-07Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersTomohiro HigaEstimatedSEC 8-K →
2024-12-17Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersChihiro SaitoEstimatedSEC 8-K →

Company news

View all →

Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Seeking Alpha Feed2026-09-17
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
globenewswire.com2026-09-03
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
marketbeat.com2026-08-18
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Yahoo2026-08-05
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com2026-07-14

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TNYA and 5,000+ tickers.

Create a free account — keep TNYA

For your agent

GET /api/data?ticker=TNYA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt